Among the other APIs currently in clinical trials for treating anemia in patients suffering from chronic kidney disease, only the HIF prolyl hydroxylase inhibitor vadadustat inhibited AspH activity substantially (Table 3, entry 19). This evidence concerns the gene ASPH and chronic kidney disease.